INS and type 2 diabetes mellitus: Many T2DM patients eventually require injectable glucose‐lowering therapy, such as glucagon‐like peptide‐1 receptor agonist or insulin when a combination of rally administered antihyperglycemic agents (OHAs) fails to maintain the desired glycemic targets.